GSK, MMV Announce Commencement of Phase III Programme of Tafenoquine for Plasmodium Vivax Malaria
April 28, 2014 at 06:43 AM EDT
GlaxoSmithKline (NYSE: GSK) and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme to ...